308 related articles for article (PubMed ID: 23242593)
21. Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources.
Arandi N; Haghpanah S; Safaei S; Zahedi Z; Ashrafi A; Eatemadfar P; Zarei T; Radwan AH; Taher AT; Karimi M
Transfus Med; 2015 Feb; 25(1):8-12. PubMed ID: 25801075
[TBL] [Abstract][Full Text] [Related]
22. Mineral Levels in Thalassaemia Major Patients Using Different Iron Chelators.
Genc GE; Ozturk Z; Gumuslu S; Kupesiz A
Biol Trace Elem Res; 2016 Mar; 170(1):9-16. PubMed ID: 26179086
[TBL] [Abstract][Full Text] [Related]
23. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial.
Premawardhena A; Perera C; Wijethilaka MN; Wanasinghe SK; Rajakaruna RHMG; Samarasinghe RANKK; Williams S; Mettananda S
BMJ Open; 2024 Feb; 14(2):e077342. PubMed ID: 38331857
[TBL] [Abstract][Full Text] [Related]
25. Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy.
Vlachaki E; Ioannidou-Papagiannaki E; Tziomalos K; Haralambidou-Vranitsa S; Perifanis V; Klonizakis I; Athanassiou-Metaxa M
Eur J Haematol; 2007 Jan; 78(1):48-51. PubMed ID: 17042774
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.
Ricchi P; Meloni A; Pistoia L; Gamberini MR; Cuccia L; Allò M; Putti MC; Spasiano A; Rosso R; Cecinati V; Righi R; Renne S; Peritore G; Vallone A; Positano V; Quaia E; Cademartiri F; Pepe A
Blood Transfus; 2024 Jan; 22(1):75-85. PubMed ID: 37146300
[TBL] [Abstract][Full Text] [Related]
27. Chelation therapy for iron overload.
Barton JC
Curr Gastroenterol Rep; 2007 Mar; 9(1):74-82. PubMed ID: 17335681
[TBL] [Abstract][Full Text] [Related]
28. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
[TBL] [Abstract][Full Text] [Related]
29. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
Voskaridou E; Christoulas D; Terpos E
Br J Haematol; 2011 Sep; 154(5):654-6. PubMed ID: 21615376
[No Abstract] [Full Text] [Related]
30. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Niemeyer C; Bassler D
Cochrane Database Syst Rev; 2010 Aug; (8):CD007477. PubMed ID: 20687088
[TBL] [Abstract][Full Text] [Related]
31. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
Waheed N; Ali S; Butt MA
J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With β-Thalassemia Major: An Experience From North India.
Parakh N; Chandra J; Sharma S; Dhingra B; Jain R; Mahto D
J Pediatr Hematol Oncol; 2017 Apr; 39(3):209-213. PubMed ID: 28221264
[TBL] [Abstract][Full Text] [Related]
33. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Saliba AN; El Rassi F; Taher AT
Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
[TBL] [Abstract][Full Text] [Related]
34. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
[TBL] [Abstract][Full Text] [Related]
35. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
Porter JB; Shah FT
Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
[TBL] [Abstract][Full Text] [Related]
36. Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.
Elalfy MS; Abdin IA; El Safy UR; Ibrahim AS; Ebeid FS; Salem DS
Hematol Oncol Stem Cell Ther; 2010; 3(4):174-8. PubMed ID: 21150236
[TBL] [Abstract][Full Text] [Related]
37. Characterisation of individual ferritin response in patients receiving chelation therapy.
Borella E; Oosterholt S; Magni P; Della Pasqua O
Br J Clin Pharmacol; 2022 Aug; 88(8):3683-3694. PubMed ID: 35199367
[TBL] [Abstract][Full Text] [Related]
38. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
McLeod C; Fleeman N; Kirkham J; Bagust A; Boland A; Chu P; Dickson R; Dundar Y; Greenhalgh J; Modell B; Olujohungbe A; Telfer P; Walley T
Health Technol Assess; 2009 Jan; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
[TBL] [Abstract][Full Text] [Related]
40. Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?
Forni GL; Kattamis A; Kuo KHM; Maggio A; Sheth S; Taher AT; Viprakasit V
Pediatr Blood Cancer; 2024 Aug; 71(8):e31035. PubMed ID: 38753107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
